Silexion Therapeutics CORP 8-K filings

Silexion Therapeutics announced progress in its Phase 2/3 clinical program for SIL204 in pancreatic cancer, alongside its second-quarter financial results, which showed increased R&D expenses and a net loss.

Silexion Therapeutics Corp. filed a Form 8-K detailing a recent shareholder meeting approving a reverse stock split and providing updated financial statements, highlighting ongoing financial challenges.

Silexion Therapeutics Corp. announced the pricing of a public offering, raising approximately $2.5 million to advance its SIL204 clinical trial.

Silexion Therapeutics Corp. has provided an updated timeline for its SIL204 product candidate, detailing progress in its Phase 2/3 clinical program for KRAS-driven cancers.

Silexion Therapeutics Corp. has appointed Avner Lushi to its Audit Committee, restoring full compliance with Nasdaq listing rules following a prior director's resignation.

Silexion Therapeutics Corp. announced the resignation of Professor Amnon Peled from its Board of Directors, effective August 1, 2026, due to personal reasons.

Silexion Therapeutics has successfully initiated its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, marking a transition to active clinical execution.

Silexion Therapeutics Corp shareholders approved an increase in authorized share capital and the exercisability of certain warrants.

Silexion Therapeutics Corp implemented a 1-for-10 reverse share split and adjusted warrants to maintain Nasdaq listing compliance.

Silexion Therapeutics Corp. announced a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and support its ongoing development of RNAi therapies.

Silexion Therapeutics announced first quarter 2026 financial results and provided an update on its Phase 2/3 clinical trial for SIL204 in pancreatic cancer, which has received Israeli Ministry of Health approval and submitted a CTA to Germany.

Silexion Therapeutics has entered into an inducement agreement to exercise existing warrants for $1.0 million in gross proceeds.

Silexion Therapeutics announced positive preclinical results for its lead candidate SIL204, showing increased MHC-I expression in KRAS-mutated pancreatic cancer cells.

Silexion Therapeutics announces initiation of GMP clinical supply manufacturing for its SIL204 therapy and receives ethics committee approval for its Phase 2/3 trial in pancreatic cancer.

Silexion Therapeutics has successfully submitted a Clinical Trial Application (CTA) to Germany's BfArM for a Phase 2/3 trial of its SIL204 therapy for KRAS-driven pancreatic cancer.

Silexion Therapeutics Corp's Board of Directors unanimously removed Ilan Levin as a board member, effective immediately.

Silexion Therapeutics Corp. announced it received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer.

Silexion Therapeutics Corp. shareholders voted against proposals to increase authorized share capital and expand its equity incentive plan at a reconvened extraordinary general meeting.

Silexion Therapeutics Corp. presented its next-generation RNAi therapeutic, SIL204, targeting KRAS mutations in historically undruggable cancers, with Phase 2/3 trials for pancreatic cancer set to begin in Q2 2026.

Silexion Therapeutics released a CEO letter detailing significant 2025 achievements, including positive preclinical data for SIL204, and outlining plans for Phase 2/3 clinical trial initiation in H1 2026.

Silexion Therapeutics announced the submission of its Phase 2/3 clinical trial application in Israel for SIL204, targeting locally advanced pancreatic cancer.

Silexion Therapeutics received positive feedback from the German health authority on its Phase 2/3 clinical trial design for SIL204 in pancreatic cancer, reinforcing its Q2 2026 trial initiation target.

Silexion Therapeutics successfully completed toxicology studies for its next-generation RNA silencing therapy, SIL204, paving the way for Phase 2/3 clinical trials in pancreatic cancer.

Silexion Therapeutics announced strong third-quarter 2025 financial results, significantly strengthening its balance sheet and advancing its lead RNAi therapy, SIL204, towards Phase 2/3 clinical trials.

Silexion Therapeutics announced positive new human cell line data for SIL204, confirming pan-KRAS activity with up to 99.7% inhibition and first evidence in gastric cancer.

Silexion Therapeutics Corp entered into an At The Market Offering Agreement to sell up to $13.17 million in ordinary shares through H.C. Wainwright & Co., LLC.

Silexion Therapeutics Corp. announced it has regained full compliance with Nasdaq's minimum bid price and shareholders' equity listing requirements.

Silexion Therapeutics Corp. announced it has regained compliance with Nasdaq's minimum shareholders' equity requirement, reporting approximately $9.41 million in equity following recent capital-raising activities.

Silexion Therapeutics completed a public offering, raising $6.0 million to fund its RNAi cancer therapies and general corporate purposes.

Silexion Therapeutics announced positive preclinical data for SIL204, demonstrating its reach and activity in major pancreatic cancer metastatic sites following systemic administration.